Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/10/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
11/09/2022* -- Results Q3 2022 -- -0.10 --
08/11/2022 -- Results Q2 2022 -0.07 -0.09 25.53%
08/11/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/09/2022 -- Results Q1 2022 -0.09 -0.11 14.29%
05/09/2022 16:30 EST Earnings Call Q1 2022 -- -- --
03/10/2022 -- Results Q4 2021 -0.10 -0.08 -19.05%
03/10/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/09/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/11/2022
Beat/Miss Upgrade
Return Since 14.63%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.
URL https://www.geron.com
Investor Relations URL https://ir.geron.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 09, 2022 (est.)
Last Earnings Release Aug. 11, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
48.92%
-57.23%
-13.04%
-44.44%
36.00%
16.91%
-23.27%
92.62%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-9.34%
35.55%
-29.98%
-1.53%
-46.08%
-30.87%
-2.21%
16.59%
12.42%
8.63%
-27.61%
2.97%
-9.92%
7.88%
-6.62%
29.96%
-11.09%
--
--
--
--
--
95.51%
41.22%
-30.35%
19.24%
-13.50%
7.72%
-12.91%
27.86%
0.39%
2.89%
24.04%
As of August 12, 2022.

Profile

Edit
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.
URL https://www.geron.com
Investor Relations URL https://ir.geron.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 09, 2022 (est.)
Last Earnings Release Aug. 11, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter GERN Tweets